AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
MoonLake Immunotherapeutics Class A Ordinary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00XQZQVP7
11.85▼ 0.49 (-3.97%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
12.34
Day's Range
11.48 – 12.28
52-Week Range
9.31 – 23.29
Volume
1.9M
Avg Volume
2.0M
Share Statistics
Shares Outstanding
Employees
130
Exchange
XNAS
Listed
2022-04-06
Share count as of August 1, 2026

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)
What is MoonLake Immunotherapeutics Class A Ordinary Shares's Market Cap?
MoonLake Immunotherapeutics Class A Ordinary Shares's Market Cap is $1.0B, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's Enterprise Value?
MoonLake Immunotherapeutics Class A Ordinary Shares's Enterprise Value is $630.1M, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's EV / EBITDA?
MoonLake Immunotherapeutics Class A Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's Net Income (TTM)?
MoonLake Immunotherapeutics Class A Ordinary Shares's Net Income (TTM) is -$263.7M, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's EBITDA?
MoonLake Immunotherapeutics Class A Ordinary Shares's EBITDA is -$265.1M, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's Diluted EPS (TTM)?
MoonLake Immunotherapeutics Class A Ordinary Shares's Diluted EPS (TTM) is -3.10, based on as-reported figures from SEC (XBRL) filings.
What is MoonLake Immunotherapeutics Class A Ordinary Shares's Net Debt?
MoonLake Immunotherapeutics Class A Ordinary Shares's Net Debt is -$378.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MLTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
Total operating expenses
Operating loss
Interest expense
Other income, net
Loss before income tax
Income tax expense
Net loss
Of which: net loss attributable to controlling interests shareholders
Of which: net loss attributable to noncontrolling interests shareholders
Comprehensive loss attributable to controlling interests shareholders
Comprehensive loss attributable to noncontrolling interests
Basic net loss per share attributable to controlling interest shareholders (USD per share)
Diluted net loss per share attributable to controlling interest shareholders (USD per share)